{"url_path":"/sec/hrmy/8-k/2026-07-16/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-084095-index.html","accession_number":"0001104659-26-084095","cik":"0001802665","ticker":"HRMY","issuer_name":"Harmony Biosciences Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-084095-index.html","primary_entity_key":"0001802665","primary_entity_name":"Harmony Biosciences Holdings, Inc."},"word_count":327,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n*Departure of Chief Financial Officer*\n\nOn July 16, 2026, the Company announced that Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.\n\n​\n\nIn connection with his departure from the Company, on July 16, 2026, the Company and Harmony Biosciences Management, Inc. entered into a Separation Agreement with Mr. Reicin (the “Separation Agreement”), pursuant to which Mr. Reicin will be entitled to receive the severance payments and benefits in accordance with his employment agreement and a pro-rated target bonus, in exchange for a release of claims in favor of the Company and its affiliates and continued compliance with the Separation Agreement and any restrictive covenants.\n\n​\n\nThe foregoing description of the Separation Agreement is not complete and is subject to and qualified in its entirety by the terms of the Separation Agreement, a copy of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.\n\n*Appointment of Interim Principal Financial Officer*\n\nOn July 16, 2026, the Board of Directors of the Company appointed Stephen Mollichella, the Company’s Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026. Mr. Mollichella brings more than two decades of finance and accounting leadership experience across publicly traded biopharmaceutical and medical technology companies.  Since joining the Company in 2021, he has played a key role in leading the Company’s financial accounting and reporting functions, building the Company’s accounting team and key financial systems, overseeing key financial governance and control processes and supporting the Company’s business development activities.\n\nMr. Mollichella has no family relationships with any director or executive officer of the Company. There are no transactions involving Mr. Mollichella that would be required to be reported under Item 404(a) of Regulation S-K."}